Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics Inc. (NASDAQ: CORT) generates frequent news as a commercial-stage pharmaceutical company focused on cortisol modulation in endocrinology, oncology, metabolic disease and neurology. Company updates often highlight progress with Korlym, which Corcept describes as the first FDA-approved medication for patients with endogenous hypercortisolism, and with a pipeline of selective glucocorticoid receptor antagonists and other cortisol modulators.
News about Corcept commonly covers clinical trial milestones in hypercortisolism, solid tumors, ALS and liver disease. Examples include data from the CATALYST program in patients with difficult-to-control type 2 diabetes and hypercortisolism, the pivotal ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, the BELLA Phase 2 trial in gynecologic cancers, the MONARCH Phase 2b trial in MASH, and the DAZALS trial of dazucorilant in ALS. Company communications also describe upcoming or ongoing studies of nenocorilant in combination with immunotherapy in solid tumors.
Investors following CORT news will see regular regulatory and corporate announcements, such as New Drug Application (NDA) submissions and FDA acceptance for review of relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application (MAA) to the European Medicines Agency, and an FDA Complete Response Letter requesting additional evidence of effectiveness for relacorilant in hypertension secondary to hypercortisolism. Quarterly earnings releases and corporate updates, reported via press releases and Form 8-K filings, provide information on product revenue from Korlym, operating expenses and the company’s cash and investment position.
This CORT news page on Stock Titan aggregates these public disclosures so readers can monitor Corcept’s clinical data presentations, regulatory milestones, financial results and other material events in one place. Users interested in endocrine disorders, ovarian cancer, MASH, ALS or cortisol biology can review the evolving news flow to understand how Corcept’s programs are progressing over time.
Corcept Therapeutics (NASDAQ: CORT) will report its third-quarter financial results and provide a corporate update on November 3, 2022. A conference call is scheduled for 5:00 p.m. ET, where participants will need to register in advance. Corcept is known for its proprietary compounds that modulate cortisol effects, targeting numerous serious conditions, including Cushing’s syndrome and various cancers. The company’s drug, Korlym®, is FDA-approved for Cushing’s syndrome.
Corcept Therapeutics (NASDAQ: CORT) has initiated DAZALS, a Phase 2 trial evaluating its cortisol modulator, dazucorilant, for treating ALS (amyotrophic lateral sclerosis). The 198-patient, randomized, double-blind, placebo-controlled study aims to assess the drug's efficacy in improving ALS symptoms and safety. Dazucorilant has shown promising results in animal models, enhancing motor performance and reducing neuroinflammation. This partnership with TRICALS, an ALS academic consortium in Europe, highlights Corcept's commitment to addressing the unmet needs in ALS treatment.
Corcept Therapeutics (CORT) reported Q2 2022 revenue of $103.4 million, an increase from $91.6 million in Q2 2021. The company reiterated its 2022 revenue guidance of $400 - $430 million. Net income for the quarter was $27.4 million or $0.24 per share, up from $0.21 in the prior year. Cash and investments rose to $382.0 million, reflecting solid growth. Corcept continues to advance clinical trials for relacorilant, addressing conditions such as platinum-resistant ovarian cancer and Cushing’s syndrome, with completion of multiple Phase 2 trials expected by year-end.
Corcept Therapeutics (NASDAQ: CORT) will report its second quarter financial results and provide a corporate update on August 3, 2022, with a conference call at 5:00 p.m. ET. The company has a robust portfolio of proprietary compounds targeting cortisol modulation for severe disorders, including Cushing’s syndrome and cancers. They are also working on clinical trials for other conditions. The call will be accessible through registration, and a replay will be available on their website.
Corcept Therapeutics announced the initiation of the ROSELLA Phase 3 trial for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. The previous Phase 2 trial demonstrated improved progression-free survival, duration of response, and overall survival without increasing side effects. The pivotal trial aims to enroll 360 women and is critical as limited treatment options exist for this patient population. Success could establish relacorilant as a new standard of care.
Corcept Therapeutics has announced the initiation of a registrational Phase 3 trial for relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. The decision follows a successful Phase 2 study showing significant improvements in progression-free survival, duration of response, and overall survival without added side effects. The new trial, named ROSELLA, aims to enroll 360 women and is designed to replicate the positive outcomes observed previously. Results will be presented at the ASCO Annual Meeting.
Corcept Therapeutics (NASDAQ: CORT) reported Q1 2022 results with revenue of $93.7 million, up from $79.4 million in Q1 2021. The diluted net income per share rose to $0.20, compared to $0.18 a year earlier. The company reiterated its 2022 revenue guidance of $400 - $430 million. Cash and investments increased to $368.1 million as of March 31, 2022. Corcept is advancing multiple clinical trials, notably in platinum-resistant ovarian cancer and Cushing’s syndrome, with a pivotal trial expected soon. A conference call was held on May 5, 2022.
Corcept Therapeutics (NASDAQ: CORT) will report its first quarter financial results on May 5, 2022, followed by a corporate update and a conference call at 5:00 p.m. ET. The company specializes in cortisol modulation and has developed a portfolio of proprietary compounds for serious disorders, including Cushing's syndrome. Korlym®, its flagship drug, was the first FDA-approved treatment for Cushing's. Details for joining the call are provided, ensuring access for investors and stakeholders.
Corcept Therapeutics announced key appointments in leadership roles to enhance commercial and development initiatives. Daniel Einhorn was appointed Vice President of Endocrine Strategy, bringing over 30 years of experience in clinical endocrinology. Amiel Balagtas joins as Vice President of Development Operations, with a strong background from Gilead Sciences. Lyndah Dreiling is the new Vice President of Global Oncology Development, adding extensive experience in drug development. These leadership changes aim to strengthen Corcept's position in treating severe disorders through innovative drug solutions.
Corcept Therapeutics (NASDAQ: CORT) has announced the completion of enrollment for its GRATITUDE trial, investigating miricorilant as a treatment for weight gain induced by antipsychotics in patients with schizophrenia or bipolar disorder. The trial, which includes 600 mg of miricorilant or placebo daily over 12 weeks, aims to evaluate weight reduction and safety. Data is expected in Q4 2022. Additionally, the company is conducting a second trial, GRATITUDE II, for long-term antipsychotic-induced weight gain, with results also due in Q4. Both studies are vital for addressing metabolic side effects of antipsychotics.